Sirius Therapeutics, a San Diego, CA-based developer of siRNA therapeutics for sufferers with power illnesses, raised practically $50M in Sequence B2 funding.
The spherical was led by an undisclosed investor, with participation from BioTrack Capital, and current buyers OrbiMed, Creacion Ventures, and Hankang Capital.
The corporate intends to make use of the funds to advance scientific improvement of its new siRNA therapeutics for cardiometabolic problems and the expansion of its new RNA supply applied sciences.
Based in 2021 and led by CEO Dr. Qunsheng Ji, Sirius develops siRNA therapeutics for sufferers with power illnesses globally. It established an innovation middle in america and a translational drugs middle in China devoted to options for the remedy and administration of power illnesses.
The corporate has raised practically $150M up to now.
FinSMEs
10/05/2025
